MiniMed Group (NASDAQ:MMED) Sets New 1-Year Low – What’s Next?

MiniMed Group Inc (NASDAQ:MMED) reached a new 52-week low during trading on Thursday . The company traded as low as $13.52 and last traded at $14.03, with a volume of 44988 shares changing hands. The stock had previously closed at $14.48.

Key Headlines Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays began coverage of MMED, adding institutional visibility that can attract new investors and liquidity. Barclays Begins Coverage on MiniMed Group (NASDAQ:MMED)
• Positive Sentiment: Goldman Sachs initiated coverage, which could lead to influential research notes and a wider investor audience. MiniMed Group (NASDAQ:MMED) Coverage Initiated at The Goldman Sachs Group
• Positive Sentiment: William Blair started coverage, increasing sell‑side analyst coverage depth for MMED. William Blair Begins Coverage on MiniMed Group (NASDAQ:MMED)
• Positive Sentiment: Evercore initiated coverage; market reaction may follow once research reports include price targets or model updates. MiniMed Group (NASDAQ:MMED) Coverage Initiated at Evercore
• Positive Sentiment: Wells Fargo launched coverage, adding another large institutional viewpoint that can influence flows. Wells Fargo & Company Initiates Coverage on MiniMed Group (NASDAQ:MMED)
• Positive Sentiment: Piper Sandler initiated coverage, broadening regional and healthcare-focused analyst attention. Piper Sandler Initiates Coverage on MiniMed Group (NASDAQ:MMED)
• Positive Sentiment: Deutsche Bank began coverage, which may introduce European investor interest. Deutsche Bank Aktiengesellschaft Begins Coverage on MiniMed Group (NASDAQ:MMED)
• Positive Sentiment: Citigroup initiated coverage, another large‑cap research voice now following MMED. MiniMed Group (NASDAQ:MMED) Coverage Initiated at Citigroup
• Positive Sentiment: BTIG started coverage, adding specialty/healthcare‑focused analyst attention. MiniMed Group (NASDAQ:MMED) Coverage Initiated at BTIG Research
• Positive Sentiment: Mizuho began coverage, further expanding the sell‑side footprint. Mizuho Begins Coverage on MiniMed Group (NASDAQ:MMED)
• Positive Sentiment: Morgan Stanley initiated coverage, which could be particularly impactful if accompanied by a price target. Morgan Stanley Begins Coverage on MiniMed Group (NASDAQ:MMED)
• Positive Sentiment: Bank of America started coverage, adding another major distribution channel for research on MMED. Bank of America Initiates Coverage on MiniMed Group (NASDAQ:MMED)

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Barclays started coverage on shares of MiniMed Group in a research note on Wednesday. They set an “overweight” rating and a $26.00 price target on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of MiniMed Group in a report on Tuesday. They issued a “buy” rating and a $20.00 target price on the stock. Wall Street Zen raised shares of MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Piper Sandler began coverage on MiniMed Group in a research report on Tuesday. They issued a “neutral” rating and a $16.00 price target for the company. Finally, Mizuho initiated coverage on MiniMed Group in a research note on Tuesday. They set an “outperform” rating and a $21.00 price objective on the stock. Eleven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, MiniMed Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Stock Performance

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.